Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SF2a-TT15 vaccine in healthy volunteers
NCT02797236Phase 1Completed
- Sponsor
- Institut Pasteur
- Start
- Sep 2016
- Primary completion
- Jun 2017
- Modality
- Bivalent/Multivalent Binders, Recombinant Proteins and Enzymes, Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of SF2a-TT15 in shigellosis (6 arms), sponsored by Institut Pasteur. Primary endpoint: Adverse Event at 12 months. Started Sep 2016; status: completed.
02
Drugs
SF2a-TT15
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT02797236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02797236.